# Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

> **NCT02219178** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 42 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** Subcutaneous bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02219178
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2019-10-31
- **Final completion:** 2020-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219178, "Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02219178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*